Fasken acted as Canadian counsel to Zomedica Pharmaceuticals Corp. (Zomedica) in connection with a registered direct offering under a “shelf” registration and a private placement under United States Securities laws. Zomedica is an animal health company focused on meeting the needs of clinical veterinarians in ways that promote both patient and practice health.
Fasken advised Zomedica on Canadian securities law requirements in connection with the registered direct offering with a team that included Bruce MacPhail and Matthew Bennett.
